A method is described for analyzing the association of the opiate narcotic levorphanol with brain tissue into three components: nonsaturable, saturable nonspecific, and saturable stereospecific. The method may be of general applicability for the study of the interaction of drugs with body tissues. In mouse brain the stereospecific binding of levorphanol represents only 2% of the total association of drug with tissue, and it was found only in certain membrane fractions. The material responsible for the stereospecific binding might be the opiate receptor.
Pharmacologic action of a drug presupposes interaction of drug molecules with tissue receptors. Progress has been made in identifying and isolating some drug receptors (1, 2) , especially where specificity and affinity happened to be very high (3) , or where a specific site-directed label could be attached irreversibly (4, 5) . For most drugs, however (including the opiate narcotics), direct measurement of localization and binding in tissues is unlikely to yield useful information about cellular or subcellular receptor sites, until two methodologic obstacles are understood and surmounted. 1 . Specificity Many drugs interact nonspecifically with a wide variety of tissue components. Localization of drug in a particular organ, subcellular particle, or macromolecule does not necessarily imply a site of action there.
We distinguish between nonsaturable and saturable interactions. Nonsaturable interactions are of two kinds. First, particles surrounded by an osmotic membrane (e.g., synaptosomes) or having a spongy matrix can contain trapped drug in aqueous solution. Second, membranes will contain dissolved drug in amounts determined by the lipid/water partition coefficient and the ambient aqueous concentration. The mere finding that drug molecules are associated with some subcellular fractions cannot be interpreted as drug "binding".
Nonspecific saturable interaction arises through ionic bonds, hydrogen bonds, and hydrophobic forces. Cationic drugs like the opiate narcotics can be expected to interact nonspecifically with anionic groups of proteins, nucleic acids, phospholipids, sphingolipids, and mucopolysaccharides-interactions that are likely to be pharmacologically irrelevant. The problem is how to sort out the nonsaturable and nonspecific saturable interactions in order to measure a relatively small amount of specific saturable interaction, at the receptor sites, where drug binding triggers the chain of events that leads to the characteristic pharmacologic effect.
The opiate narcotics display an extraordinary degree of stereospecificity. Whereas the D(-) compounds are pharmacologically active, the L(+) isomers are neither agonists nor antagonists, and therefore presumably cannot enter the receptor sites. We take advantage of this by using radioactive levorphanol [a synthetic D(-) congener of morphine] and its nonradioactive enantiomer, dextrorphan, in the following way (Fig. 1 ). Most pharmacologic effects are readily reversible, whence it is supposed that the corresponding drug-receptor interactions are also reversible. Dilution of a reversible system promotes ligand dissociation, and this may occur to a significant extent during manipulation of tissue fractions prior to analysis. The problem is analogous to the "dilution effect" whereby an enzyme inhibited reversibly in vivo recovers activity if diluted prior to assay (6) . Tissues are usually homogenized in several volumes of aqueous medium; but even if no water is added (7), the mixing of intracellular and interstitial fluids might cause dilution artifacts. Fractionation methods also entail dilution. In density-gradient centrifugation, as in simple sedimentation, drug molecules will dissociate from particles as they move down the tube, to be collected with components that band at higher levels, which will lead to spurious results. In molecular-sieving techniques, progressive dilution occurs down the length of the column. Acid precipitation of soluble macromolecules releases bound ligands to an unpredictable extent.
Seeing no meaningful way to assess the stereospecific binding of a drug in vivo, we decided to study the capacity of tissue fractions to bind in vitro. The essential precaution was to prevent dissociation of reversibly-bound drug by maintaining ambient drug concentrations constant throughout all procedures. Particulate material was fractionated (or simply sedimented) centrifugally in the presence of the appropriate radioactive and nonradioactive drugs (conditions A, B, and C), and the excess radioactivity associated with the bands and pellets was measured. For soluble and some particulate fractions, molecular sieving columns were used. Here the method of Hummel and Dreyer (8) suited our requirements perfectly, the column being first equilibrated with the appropriate drugs. Equilibrium dialysis was suitable for measuring the binding capacity of soluble fractions.
METHODS
Male Swiss-Webster mice (25-30 g) were used. Usually, 3-6 brains were pooled. After decapitation, whole brains or portions thereof were weighed quickly and homogenized in 10 volumes of cold 0.32 M sucrose in 0.01 M Tris 1 HCl, pH 7.0, with a loose-fitting motor-driven pestle, exactly as described by Whittaker and Dowe (9) . In another procedure, tissue was homogenized by hand in 0.25 M sucrose-Tris in a Dounce homogenizer with 10 strokes of the A pestle (clearance 0.1 mm). CaCl2 (10 MM) was added for further workup of the crude mitochondrial fraction (10) .
For experiments with portions of brain, the cerebellum and cerebrum were dissected off and a cut was made at the rostral border of the pons, yielding a medulla-pons portion and a portion consisting mainly of diencephalic structures.
Levorphanol (3- (26.6 suCi/mg), and ditritiated [6,7- 'H]levorphanol, at 3.0 ACi/mg and at 36.7 ;Ci/mg) were generously donated by Hoffmann-LaRoche, Inc. The 14C-and 'H-labeled drugs were used interchangeably; no differences were observed. All drug concentrations are given in terms of free base.
Radioactivity was determined by liquid scintillation (Fig. 1) . Levorphanol or dextrorphan (50 jig/ml) was added to the appropriate tube Pellets were dissolved in 1 ml of 0.1 N NaOH, and samples were taken for radioactivity counting. Sephadex and DEAE-Cellulose Columns. The methods of Marchbanks (16) and Hummel and Dreyer (8) were used. Three Sephadex G-50 columns (1 X 10 cm) were equilibrated with 15 ml of radioactive levorphanol (0.5 Mg/ml) in 0.32 M sucrose-Tris (A), or the same medium containing also 50 ,ug/ml nonradioactive dextrorphan (B) or levorphanol (C).
Aliquots from a suspension of mitochondrial fraction (10 ml/g brain tissue) were incubated at 25°C for 15 min at the same drug concentrations used on the columns. Then 0.5 ml from each incubation mixture was placed on the corresponding column. Elution was with 15 ml of additional equilibration medium, and 1-ml fractions were collected and assayed for radioactivity and protein. The soluble supernatant from homogenate was fractionated on DEAE-cellulose as described elsewhere (17) , with the exceptions noted in the text.
Equilibrium Dialysis of Soluble Fractions. 1-ml aliquots of soluble fractions or buffer alone in 6-mm Viscose dialysis tubing bags were placed in capped 10-ml polypropylene tubes containing 4 ml of 0.32 M sucrose-Tris. Dextrorphan was added to the medium bathing the bag in B tubes, levorphanol in C tubes, and radioactive levorphanol in A, B, and C tubes.
After vigorous agitation on a reciprocal shaker for 18 (18) .
RESULTS
We first show how the methodology described above clarifies an otherwise misleading result. Fig. 2 shows some levorphanol associated with the crude mitochondrial peak (fraction 25), a finding that has been interpreted by others (19) as a synaptosomal "binding" of opiate molecules. However, when this interaction was studied by the A, B, and C systems described, a different conclusion was reached. As shown in Fig. 3 , levorphanol associated with the particles in A was reduced by about one-half in B, and there was no further reduction in C. Thus, about half the total "binding" was of the nonspecific saturable kind, the remainder was due to trapped and dissolved drug; there was no detectable stereospecific binding.
Whole-brain homogenate was incubated with radioactive levorphanol under conditions A, B, and C. Then the particulate material was sedimented to obtain the data of Table 1. The concentration of radioactive levorphanol (0.5 Ag/ml, 1.95 MM) was well within the pharmacologically relevant range of brain levels determined in vivo (ref. 7 and Goldstein and Judson, to be published). In each of eight brains about half the total interaction was due to nonspecific binding, and nearly half to trapped and dissolved drug. There was also a significant, though small, B minus C difference, representing stereospecific binding, about 2% of the total.
The same technique was applied to the various particulate fractions and subfractions (Table 2 ). Significant stereospecific binding was found in the crude nuclear fraction and in membranes from that fraction after lysis, in membranes from the lysed crude mitochondrial fraction, and in the crude micro- Data are means ±SE, based on B minus C differences, as described in text. For fractionation procedures see Methods. Membranes of the crude nuclear fraction were obtained by sedimenting at 105,000 X g for 1 hr after ultrasonic treatment. n is number of separate experiments, usually 3-6 pooled mouse brains in each. Entries under mg protein are for the given fraction in a single brain; total brain protein is sum of homogenate particulate and soluble supernatant. P is significance of difference from zero, by t test; N.S. = P > 0.05. Except as noted below, concentration of radioactive levorphanol was 0.5jMg/mi (1.95)AM). Fig. 3 ) in the presence of dextrorphan (condition B). Recovery of protein was 98%, and 11 well-defined peaks were obtained.
In none of the 152 fractions was there significant increase in radioactivity above the equilibrium level in the eluting solutions, with the following exception. A protein peak eluted by shifting from 2 M NaC1 back to salt-free Tris buffer (0.005 M) had twice the equilibrium level of radioactivity. When this peak was further studied on Sephadex G-10, exactly as in Fig. 3 , no B minus C difference was found; thus the binding was not stereospecific.
Since stereospecific binding could be measured only as a small difference between large numbers (compare Table 1 ), variability was high. We found, however, that a 20-fold higher concentration of radioactive levorphanol (with the same 100:1 ratio of nonradioactive to radioactive drug in conditions B and C) yielded larger and more consistent values for the binding (Table 3) . Most of the stereospecific-binding Methods and presentation of data as in Table 2 , except as follows. Concentration of radioactive levorphanol was 10,Mg/ml (39 MAM). Crude nuclear and crude mitochondrial pellets were sedimented (after incubation with levorphanol) at 20,000 X g for 15 min. Floated membranes were obtained from the crude nuclear fraction as described under Methods. capacity in homogenate appeared in the crude nuclear fraction, and this was nearly all accounted for in membranes floated on 2 M sucrose after sedimentation of nuclei. Little of this capacity was in the crude mitochondrial, and none in the crude microsomal fraction. The floated membranes were enriched in stereospecific-binding capacity per mg protein as compared with homogenate or any other fraction.
As reported in a preliminary communication (20) , the floated membranes retain their stereospecific-binding capacity after extraction of 70% of the protein by Triton X-100 or sodium dodecyl sulfate, provided the detergent is removed by dialysis. This binding in such preparations has a pH optimum in the neutral region, is enhanced by EDTA, is greatly diminished by Ca2+ or Mg2+, and is largely abolished by treatwith neuraminidase or pronase but not trypsin. p-Chloromercuribenzoate, mercaptoethanol, and iodoacetic acid do not affect stereospecific-binding capacity. Of greatest interest, the capacity is retained nearly quantitatively in material extracted into chloroform-methanol (21) .
DISCUSSION
It may be assumed that the receptor for the D(-) opiates is stereospecific, because the L(+) isomers are neither agonists nor antagonists. Therefore, in order to identify and try to isolate opiate receptors, we developed a method for measuring stereospecific binding in the presence of nonspecific interactions. We found that about half the total association of levorphanol with brain tissue is of the nonsaturable kind (trapped and dissolved drug), nearly half is of the nonspecific saturable kind, and only about 2% is stereospecific. Consequently, it is clear that neither measurements of total "binding" (19, (22) (23) (24) nor even a direct comparison of the distributions of a D(-) narcotic and its L(+) enantiomer in brain tissue (25) could be relevant to the identification of receptor sites.
The subcellular distribution of stereospecific-binding capacity was interesting. Virtually none was found in soluble supernatant of whole homogenate, soluble axoplasmic material from nerve-ending particles, synaptic vesicles, purified nuclei or mitochondria, or myelin fractions. Stereospecific binding occurred mainly in membranes separated by flotation from the crude nuclear fraction, but also to some extent in crude mitochondrial (synaptosomal) and microsomal membrane fractions. Major regions of brain did not differ significantly in stereospecific binding, a not unexpected finding in view of the multiplicity of narcotic sites of action (26) .
Is the magnitude of stereospecific binding consistent with the possibility that it represents opiate receptor sites? After an ED50 (median effective dose) of the very potent opiate etorphine in rats, the brain concentration was 3 nM (27) . In the mouse this would be 7 X 10"1 molecules per brain. That is clearly an upper limit for the number of receptor sites that could be occupied at the ED50. In our low-concentration experiments we used a concentration of radioactive levorphanol equivalent to that established in brain at about five times the ED50 (to be published), and we found stereospecific binding to be about 1 nmol (6 X 1014 molecules) per brain. Moreover, with 20-fold higher drug concentration, we found about 10 times as much stereospecifically bound. Consequently, if these binding sites are indeed receptor sites, pharmacologic action of an opiate must require only a very low fractional occupancy of the receptors, and equal effects must not necessarily imply equal receptor occupancies. Both these postulates are already inherent in certain theories of drug action (28, 29) .
We are proceeding to purify and characterize the material responsible for the stereospecific binding. Preliminary results indicate it has some properties characteristic of proteolipids. This work was supported by research grant MH13963 from the National Institute of Mental Health.
